Amiodarone attenuates the proarrhythmic effects of dobutamine in patients with advanced congestive heart failure

Hellenic Journal of Cardiology

Volumn 50, Issue 3, 2009, Pages 193-198

  Tsagalou, Eleftheria P ^a   Gounopoulos, Pantelis ^a   Terrovitis, John V ^a   Drakos, Stavros G ^a   Katsaros, Fotios T ^a   Kaldara, Elisabeth E ^a   Alexopoulos, George P ^a   Anastasiou Nana, Maria I ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Amiodarone; Dobutamine; Heart failure; Inotropic therapy; Proarrhythmia

Indexed keywords

AMIODARONE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; FUROSEMIDE; SPIRONOLACTONE;

ADULT; AMBULATORY MONITORING; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DRUG INFUSION; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART BEAT; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; MALE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; DOBUTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 66949120745     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Collins JA, Skidmore MA, Melvin DB, Engel PJ. Home intravenous dobutamine therapy in patients awaiting heart transplantation. J Heart Transplant. 1990; 9: 205-208. (Pubitemid 20343238)
2. Gibelin P, Sbirrazzuoli V, Drici M, Camous J, Lapalus P, Morand P. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, nor epinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure. Cardiovasc Drugs Ther. 1990; 4: 1105-1111. (Pubitemid 20330475)
3. Miller LW. Outpatient dobutamine for refractory congestive heart failure: advantages, techniques, and results. J Heart Lung Transplant. 1991; 10: 482-487.
4. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J. 1986; 112: 787-791. (Pubitemid 16025043)
5. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation. 1986; 74: II-38 [abstract].
6. Ikram H, Crozier IG. Xamoterole in severe heart failure. Lancet. 1990; 336: 517-518.
7. Packer M, Carver JR, Rodeheffer RJ, et al; for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991; 325: 1468-1475.
8. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999; 138: 78-86. (Pubitemid 29331125)
9. Cohn JN, Goldstein SO, Greenberg BH, et al; for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998; 339: 1810-1816.
10. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M; and the PROFILE Investigators and Coordinators. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation. 1993; 88: I-301.
11. Cowley AJ, Skene AM; on behalf of the Enoximone Investigators. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J. 1994; 72: 226-230.
12. Stump GL, Wallace AA, Gilberto DB, Gehret JR, Lynch JJ Jr. Arrhythmogenic potential of positive inotropic agents. Basic Res Cardiol. 2000; 95: 186-198. (Pubitemid 30325894)
13. John RM, Taggart PI, Sutton PM, Ell PJ, Swanton H. Direct effect of dobutamine on action potential duration in ischemic compared with normal areas in the human ventricle. J Am Coll Cardiol. 1992; 20: 896-903.
14. David S, Zaks JM. Arrhythmias associated with intermittent outpatient dobutamine infusion. Angiology. 1986; 37: 86-91. (Pubitemid 16044084)
15. Kinder C, Chamberlin J, Kall J, et al. Prognostic significance of sustained ventricular tachyarrhythmia occurring during dobutamine infusion. J Heart Lung Transplant. 1994; 13: 1045-1050. (Pubitemid 24365586)
16. Vecchia L, Ometto R, Finocchi G, Vincenzi M. Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure. Pacing Clin Electrophysiol. 1999; 22: 397-399. (Pubitemid 29109289)
17. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995; 38: 167-180.
18. Tarjan J, Nagy L, Liziczai I, Junger E. Arrhythmic effects of intermittent dobutamine therapy in chronic heart disease failure. The Working Group of Cardiology of the Academic Committee of Veszprem, Hungary. Am J Ther. 1998; 5: 405-411.
19. Burger A, Horton D, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J. 2002; 144: 1102-1108. (Pubitemid 36026926)
20. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle; CASCADE Investigators. Am J Cardiol. 1993; 72: 70F-74F. (Pubitemid 23360758)
21. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983; 106: 788-797.
22. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994; 344: 493-498.
23. Saridakis NS, Toumanidis ST, Vintzileou AM, et al. Effect of dobutamine on left ventricular functional geometry after acute myocardial infarction: experimental study. Hellenic J Cardiol. 2007; 48: 72-79. (Pubitemid 47621097)
24. Nanas J, Kontoyannis D, Alexopoulos G, et al. Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest. 2001;119;1173-1178. (Pubitemid 32679447)
25. Nanas J, Tsagalou E, Kanakakis J, et al. Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest. 2004; 125; 1198-1204. (Pubitemid 38501329)
26. The CAPS Investigators. Cardiac Arrhythmia Pilot Study. Am J Cardiol. 1986; 57: 91-95. (Pubitemid 16136640)
27. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003; 41: 997-1003. (Pubitemid 36315544)
28. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997; 35: 13-29. (Pubitemid 27374736)
29. Du XJ, Esler MD, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation. 1995; 91: 462-470.
30. Kaye DM, Dart AM, Jennings GL, Esler MD. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J Am Coll Cardiol. 1999; 33: 1553-1559.
31. Kallergis EM, Vardas PE. Primary prevention of sudden cardiac death: apart from the defibrillator, what is important in patients with myocardial infarction or heart failure? Hellenic J Cardiol. 2007; 48: 89-93.
32. Anastasiou-Nana MI, Menlove RL, Nanas JN, Mason JW. Spontaneous variability of ventricular arrhythmias in patients with chronic heart failure. Am Heart J. 1991; 122: 1007-1015.